Asgard Therapeutics

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading provider of nucleic acids and viral vector development and manufacturing services, for process development up to clinical phases 1/2 manufacturing of its candidate AT-108, based...
Medicon Village, 223 81 Lund, Sweden

+46 (0)704878061